The FDA is seeking input on a new pilot program exploring how artificial intelligence can optimize early-phase clinical trials. Maya and Sam unpack the agency's goals—from accelerating dose selection to guiding critical go/no-go decisions—and what these proposed standards mean for pharma sponsors and AI developers.

Key points

  • The FDA identifies early-phase clinical trials as a critical bottleneck characterized by high uncertainty and inefficient decision-making processes.
  • The proposed pilot program aims to explore how AI can improve trial efficiency, enhance safety monitoring, and support earlier Phase 1 to Phase 2 decisions.
  • The FDA emphasizes that AI use must align with the NIST AI Risk Management Framework, ensuring systems are valid, safe, secure, explainable, and fair.
  • The agency is actively soliciting public input on how to structure the pilot, including which therapeutic areas to target and how to measure AI system stability and model drift.
  • Evaluating the concordance between AI-supported and traditional decision-making will be a key focus for sponsors and regulators alike.

Source: AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information - U.S. Food and Drug Administration

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/ai-at-the-bottleneck-the-fda-s-blueprint-for-smarter-early-phase-trial-85dd54

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Mike Rawson. Innehållet i podden är skapat av Mike Rawson och inte av, eller tillsammans med, Poddtoppen.